<DOC>
	<DOCNO>NCT02284880</DOCNO>
	<brief_summary>Phase I , two-centre , open-label , randomize , gender-balanced , single-dose , laboratory blind , two-period , two-sequence , crossover study 2 group 20 healthy male female subject , demonstrate bioequivalence ( BE ) two active product ingredient ( API ) source eslicarbazepine acetate ( ESL )</brief_summary>
	<brief_title>Comparative Bioavailability Study Two Different Sources Eslicarbazepine Acetate</brief_title>
	<detailed_description>Phase I , two-centre , open-label , randomize , gender-balanced , single-dose , laboratory blind , two-period , two-sequence , crossover study 2 group 20 healthy male female subject . The study consist 2 period separate wash-out least 7 day dos . To demonstrate bioequivalence ( BE ) two active product ingredient ( API ) source [ current API source - market formulation ( MF ) versus new API source - to-be-marketed ( TBM ) ] eslicarbazepine acetate ( ESL )</detailed_description>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>A sign date informed consent form studyspecific screen procedure perform , Healthy male female 18 55 age , inclusive , Had BMI within range 18 25 kg/m2 inclusive screening , Had physical examination , vital sign , electrocardiogram ( ECG ) routine laboratory test within normal range consider non clinically significant ( NCS ) Investigator , Nonsmokers smokers less 10 cigarette per day , If female , childbearing potential reason surgery ( hysterectomy , bilateral oophorectomy tubal ligation ) , childbearing potential , use one follow effective method contraception ( intrauterine device ( IUD ) abstention condom ) duration trial negative urine pregnancy test screen visit upon admission period . Had clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , endocrine , connective tissue disease disorder , clinically relevant surgical history , Presented disease condition ( medical surgical ) , opinion Investigator , may interfere absorption , distribution , metabolism excretion study drug , Had history relevant atopy drug hypersensitivity ( include know hypersensitivity eslicarbazepine acetate excipients ) , Had history alcoholism drug abuse within 1 year D 1 , Consumption 50 g ethanol per day ( 12.5 Centiliters [ cL ] glass 10째 [ 10 % ] wine = 12 g ; 4 cL aperitif , 42째 [ 42 % ] whiskey = 17 g ; 25 cL glass 3째 [ 3 % ] beer = 7.5 g ; 25 cL glass 6째 [ 6 % ] beer = 15 g ) , Use medicine within 2 week admission first treatment period could affect , Investigator 's opinion , safety subject , Had use investigational drug participate clinical trial within 2 month admission first treatment period , Had donate receive blood blood product within 2 month prior screen , Could communicate reliably investigator , unlikely cooperate requirement study , Was unwilling unable give write informed consent , If female , pregnant breastfeeding ,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>